Search

Your search keyword '"LO CURTO, M."' showing total 2 results
Start Over Author "LO CURTO, M." Publisher nature publishing group
2 results on '"LO CURTO, M."'

1. Autologous bone marrow transplantation for extramedullary relapse in childhood leukemia. The AIEOP Group and the FONOP. Italian Association of Pediatric Hemato/Oncology.

Author

Messina C, Rondelli R, Valsecchi MG, Rossetti F, Miniero R, Meloni G, Locatelli F, Aricò M, Testi AM, Dini G, Arrighini A, Manfredini L, Dallorso S, Porta F, Uderzo C, Santoro N, Werner B, De Rossi G, Loiacono G, Andolina M, Lippi A, Favre C, Amici A, Lo Curto M, and Masera G

Subjects
Adolescent, Child, Child, Preschool, Female, Humans, Infant, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Recurrence, Transplantation, Autologous, Treatment Outcome, Bone Marrow Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

The role of autologous bone marrow transplantation (ABMT) in childhood ALL after an isolated extramedullary (IE) relapse is controversial. Between December 1984 and November 1995, 52 children underwent ABMT because of an IE relapse. The data were stored in the AIEOP-BMT Registry. Thirty four children were transplanted in 2nd CR; eighteen > 2nd CR. The median duration of 1st CR was 24 (range 3-69) and 18 (range 3-59) months, respectively. The median interval from last CR to ABMT was 6 (range 1-28) and 3 (range 1-81) months, respectively. The 5 year EFS for patients transplanted in 2nd CR was 67.7%, while the 3 year EFS for patients in > 2nd CR was 16.7%. In conclusion, ABMT was an effective treatment in early IE relapse only if performed in 2nd CR.

Published
1996

2. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group.

Author

Garaventa A, Rondelli R, Lanino E, Dallorso S, Dini G, Bonetti F, Arrighini A, Santoro N, Rossetti F, Miniero R, Andolina M, Amici A, Indolfi P, Lo Curto M, Favre C, Paolucci P, Pession A, and De Bernardi B

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemical and Drug Induced Liver Injury, Child, Child, Preschool, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Infant, Infant, Newborn, Infections etiology, Infections mortality, Italy epidemiology, Liver Diseases mortality, Male, Melphalan administration & dosage, Neuroblastoma drug therapy, Neuroblastoma mortality, Neuroblastoma pathology, Neuroblastoma radiotherapy, Registries, Survival Analysis, Survival Rate, Transplantation Conditioning adverse effects, Treatment Outcome, Vincristine administration & dosage, Whole-Body Irradiation adverse effects, Bone Marrow Transplantation statistics & numerical data, Neuroblastoma therapy
Abstract

This study reports a large cooperative experience in myeloablative therapy and bone marrow rescue undertaken to define better the outcome of children with disseminated neuroblastoma after megatherapy. Between 1984 and 1993, 135 children underwent myeloablative therapy with bone marrow transplantation (BMT) in nine Italian Centres. One hundred and seventeen children received unpurged autologous BMT, five allogeneic BMT and 13 peripheral blood progenitor cells as rescue. Of these 135 children, 57 were in 1st CR, 11 in 2nd or subsequent CR, 42 in 1st PR, and 25 had more advanced disease. Twelve children (9%) died of toxicity, 86 relapsed or progressed at 1-68 months (median 7 months) and 80 of these subsequently died of progressive disease. Forty-three children are still alive with 37 in continuous remission at a median of 65 months (30-123 months) after BMT. Overall and disease-free survival at 8 years are 28.5% (s.e. 4.3) and 26% (s.e. 4), respectively. Disease-free survival is 34.6% (s.e. 6.7) for the patients grafted in 1st complete remission, 23.6% (s.e. 6.6) for patients grafted in 1st partial remission, 36.4% (s.e. 14.5) for patients grafted in 2nd or subsequent CR, and 8% (5.4) for patients with advanced disease. We conclude these data confirm that early toxicity of myeloablative therapy is manageable and that myeloablative therapy with bone marrow rescue may contribute to an improved long-term survival of children with disseminated neuroblastoma but the objective of cure of all patients remains distant.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results